Clinical observation of imatinib mesylate combined with myeloablative allogeneic hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia advanced phase
10.3760/cma.j.issn.1009-9921.2010.09.008
- VernacularTitle:伊马替尼联合异基因造血干细胞移植治疗进展期慢性粒细胞白血病六例
- Author:
Feng GAO
;
Shuqing FENG
;
Mengbo ZHU
;
Xiaocong CUI
;
Xiaoyu LI
;
Xiaomei DU
;
Xingshuang YAN
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,chronic;
Hematopoietic stem cell trasplantation;
Allogeneic;
Imatinib CAS
- From:
Journal of Leukemia & Lymphoma
2010;19(9):539-541
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the curative effect of imatinib mesylate combined with myeloablative allogeneic hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia advanced phase. Methods To retrospectively analyze clinical effect of 6 patients with chronic myeloid leukemia advanced phase were treated with imatinib mesylate combined with myeloablative allogeneic hematopoietic stem cell transplantation from July 2005 to April 2009, and literature review. Results The disease-free survival and the survival rate of 4 patients were 66.67 %. 2 patients died (one case die for Chemotherapy pretreatment in the third transplantation after two years, the other case die for Chemotherapy pretreatment in the second transplantation after six months ). Conclusion The clinical cure rate of chronic myeloid leukemia advanced phase may be improved with the treatment of imatinib mesylate combined with myeloablative allogeneic hematopoietic stem cell transplantation.
